Drugs / CAR-T cell immunotherapy
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04969354 | Oct 2021 → Sep 2025 overdue | — | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT03638206 | Mar 2018 → Mar 2023 | B-cell acute lymphoblastic leukemia, colorectal cancer, esophageal cancer, gastric cancer +11 | Shenzhen BinDeBio Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03013712 | Jan 2017 → Dec 2018 | carcinoma of esophagus, carcinoma of liver and intrahepatic biliary tract, colon carcinoma, gastric cancer +2 | First Affiliated Hospital of Chengdu Medical College | Unknown | No outcome recorded |
| Phase 1/2 | NCT03252171 | Oct 2015 → Aug 2016 | glioma | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02575261 | Sep 2015 → Aug 2016 | malignant glioma | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02723942 | Jun 2015 → Aug 2016 | hepatocellular carcinoma | Fuda Cancer Hospital, Guangzhou | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T cell immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02723942 ↗ |
| Modality | Cell therapy | “This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.” NCT02575261 ↗ |
| Route | Other | “by infusion” NCT02575261 ↗ |
| Target | GPC3 | “This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.” NCT02723942 ↗ |